{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:34:17Z","timestamp":1792197257781,"version":"4.4.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T00:00:00Z","timestamp":1491177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1038\/leu.2017.108","type":"journal-article","created":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T06:41:15Z","timestamp":1491201675000},"page":"2376-2387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["A novel AHI-1\u2013BCR-ABL\u2013DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy"],"prefix":"10.1038","volume":"31","author":[{"given":"X","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Rothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Fruhstorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Maetzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D L","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R K","family":"Humphries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,3]]},"reference":[{"issue":"1","key":"BFleu2017108_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/asheducation-2002.1.111","volume":"2002","author":"B. J. Druker","year":"2002","unstructured":"Druker BJ, O'Brien SG, Cortes J, Radich J . Chronic myelogenous leukemia. Hematol Am Soc Hematol Educ Program 2002, 111\u2013135.","journal-title":"Hematology"},{"key":"BFleu2017108_CR2","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL . Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330\u20131340.","journal-title":"N Engl J Med"},{"key":"BFleu2017108_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrc2368","volume":"8","author":"M Savona","year":"2008","unstructured":"Savona M, Talpaz M . Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer 2008; 8: 341\u2013350.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2017108_CR4","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1172\/JCI41246","volume":"120","author":"D Perrotti","year":"2010","unstructured":"Perrotti D, Jamieson C, Goldman J, Skorski T . Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010; 120: 2254\u20132264.","journal-title":"J Clin Invest"},{"issue":"Suppl 2","key":"BFleu2017108_CR5","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.3816\/CLM.2007.s.005","volume":"7","author":"X Jiang","year":"2007","unstructured":"Jiang X, Smith C, Eaves A, Eaves C . The challenges of targeting chronic myeloid leukemia stem cells. Clin Lymphoma Myeloma 2007; 7 (Suppl 2): S71\u2013S80.","journal-title":"Clin Lymphoma Myeloma"},{"key":"BFleu2017108_CR6","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872\u2013884.","journal-title":"Blood"},{"key":"BFleu2017108_CR7","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408\u20132417.","journal-title":"N Engl J Med"},{"key":"BFleu2017108_CR8","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031\u20131037.","journal-title":"N Engl J Med"},{"key":"BFleu2017108_CR9","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029\u20131035.","journal-title":"Lancet Oncol"},{"key":"BFleu2017108_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58\u201360.","journal-title":"Blood"},{"key":"BFleu2017108_CR11","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1038\/leu.2010.185","volume":"24","author":"DM Ross","year":"2010","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010; 24: 1719\u20131724.","journal-title":"Leukemia"},{"key":"BFleu2017108_CR12","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/sj.leu.2404609","volume":"21","author":"X Jiang","year":"2007","unstructured":"Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007; 21: 926\u2013935.","journal-title":"Leukemia"},{"key":"BFleu2017108_CR13","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/jnci\/djk150","volume":"99","author":"X Jiang","year":"2007","unstructured":"Jiang X, Saw KM, Eaves A, Eaves C . Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 2007; 99: 680\u2013693.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu2017108_CR14","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","volume":"121","author":"B Zhang","year":"2013","unstructured":"Zhang B, Li M, McDonald T, Holyoake TL, Moon RT, Campana D et al. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling. Blood 2013; 121: 1824\u20131838.","journal-title":"Blood"},{"key":"BFleu2017108_CR15","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ . Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121: 396\u2013409.","journal-title":"J Clin Invest"},{"key":"BFleu2017108_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319\u2013325.","journal-title":"Blood"},{"key":"BFleu2017108_CR17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc3317","volume":"12","author":"T O'Hare","year":"2012","unstructured":"O'Hare T, Zabriskie MS, Eiring AM, Deininger MW . Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 2012; 12: 513\u2013526.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2017108_CR18","doi-asserted-by":"publisher","first-page":"9046","DOI":"10.1128\/JVI.76.18.9046-9059.2002","volume":"76","author":"X Jiang","year":"2002","unstructured":"Jiang X, Hanna Z, Kaouass M, Girard L, Jolicoeur P . Ahi-1, a novel gene encoding a modular protein with WD40-repeat and SH3 domains, is targeted by the Ahi-1 and Mis-2 provirus integrations. J Virol 2002; 76: 9046\u20139059.","journal-title":"J Virol"},{"key":"BFleu2017108_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/jnci\/djt006","volume":"105","author":"M Chen","year":"2013","unstructured":"Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M et al. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. J Natl Cancer Inst 2013; 105: 405\u2013423.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu2017108_CR20","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1182\/blood-2003-11-4026","volume":"103","author":"X Jiang","year":"2004","unstructured":"Jiang X, Zhao Y, Chan WY, Vercauteren S, Pang E, Kennedy S et al. Deregulated expression in Ph+ human leukemias of AHI-1, a gene activated by insertional mutagenesis in mouse models of leukemia. Blood 2004; 103: 3897\u20133904.","journal-title":"Blood"},{"key":"BFleu2017108_CR21","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1084\/jem.20072316","volume":"205","author":"LL Zhou","year":"2008","unstructured":"Zhou LL, Zhao Y, Ringrose A, DeGeer D, Kennah E, Lin AE et al. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem\/progenitor cells. J Exp Med 2008; 205: 2657\u20132671.","journal-title":"J Exp Med"},{"key":"BFleu2017108_CR22","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1002\/pmic.201100553","volume":"12","author":"X Liu","year":"2012","unstructured":"Liu X, Chen M, Lobo P, An J, Grace Cheng SW, Moradian A et al. Molecular and structural characterization of the SH3 domain of AHI-1 in regulation of cellular resistance of BCR-ABL(+) chronic myeloid leukemia cells to tyrosine kinase inhibitors. Proteomics 2012; 12: 2094\u20132106.","journal-title":"Proteomics"},{"key":"BFleu2017108_CR23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/0378-1119(95)00275-B","volume":"163","author":"C Diatloff-Zito","year":"1995","unstructured":"Diatloff-Zito C, Gordon AJ, Duchaud E, Merlin G . Isolation of an ubiquitously expressed cDNA encoding human dynamin II, a member of the large GTP-binding protein family. Gene 1995; 163: 301\u2013306.","journal-title":"Gene"},{"key":"BFleu2017108_CR24","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00109-009-0587-4","volume":"88","author":"AC Durieux","year":"2010","unstructured":"Durieux AC, Prudhon B, Guicheney P, Bitoun M . Dynamin 2 and human diseases. J Mol Med 2010; 88: 339\u2013350.","journal-title":"J Mol Med"},{"key":"BFleu2017108_CR25","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1038\/emboj.2010.249","volume":"29","author":"C Gu","year":"2010","unstructured":"Gu C, Yaddanapudi S, Weins A, Osborn T, Reiser J, Pollak M et al. Direct dynamin-actin interactions regulate the actin cytoskeleton. EMBO J 2010; 29: 3593\u20133606.","journal-title":"EMBO J"},{"key":"BFleu2017108_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1247\/csf.10016","volume":"36","author":"N Ishida","year":"2011","unstructured":"Ishida N, Nakamura Y, Tanabe K, Li SA, Takei K . Dynamin 2 associates with microtubules at mitosis and regulates cell cycle progression. Cell Struct Funct 2011; 36: 145\u2013154.","journal-title":"Cell Struct Funct"},{"key":"BFleu2017108_CR27","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1038\/onc.2011.329","volume":"31","author":"RD Eppinga","year":"2012","unstructured":"Eppinga RD, Krueger EW, Weller SG, Zhang L, Cao H, McNiven MA . Increased expression of the large GTPase dynamin 2 potentiates metastatic migration and invasion of pancreatic ductal carcinoma. Oncogene 2012; 31: 1228\u20131241.","journal-title":"Oncogene"},{"key":"BFleu2017108_CR28","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1038\/onc.2011.436","volume":"31","author":"H Feng","year":"2012","unstructured":"Feng H, Liu KW, Guo P, Zhang P, Cheng T, McNiven MA et al. Dynamin 2 mediates PDGFRalpha-SHP-2-promoted glioblastoma growth and invasion. Oncogene 2012; 31: 2691\u20132702.","journal-title":"Oncogene"},{"key":"BFleu2017108_CR29","first-page":"2427","volume":"118","author":"AG Ramsay","year":"2008","unstructured":"Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008; 118: 2427\u20132437.","journal-title":"J Clin Invest"},{"key":"BFleu2017108_CR30","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.devcel.2013.02.010","volume":"24","author":"GL Razidlo","year":"2013","unstructured":"Razidlo GL, Wang Y, Chen J, Krueger EW, Billadeau DD, McNiven MA . Dynamin 2 potentiates invasive migration of pancreatic tumor cells through stabilization of the Rac1 GEF Vav1. Dev Cell 2013; 24: 573\u2013585.","journal-title":"Dev Cell"},{"key":"BFleu2017108_CR31","doi-asserted-by":"publisher","first-page":"E1872","DOI":"10.1073\/pnas.1400749111","volume":"111","author":"C Rosse","year":"2014","unstructured":"Rosse C, Lodillinsky C, Fuhrmann L, Nourieh M, Monteiro P, Irondelle M et al. Control of MT1-MMP transport by atypical PKC during breast-cancer progression. Proc Natl Acad Sci USA 2014; 111: E1872\u2013E1879.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2017108_CR32","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nature10725","volume":"481","author":"J Zhang","year":"2012","unstructured":"Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157\u2013163.","journal-title":"Nature"},{"key":"BFleu2017108_CR33","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3747\/co.v15i2.224","volume":"15","author":"DL Forrest","year":"2008","unstructured":"Forrest DL, Jiang X, Eaves CJ, Smith CL . An approach to the management of chronic myeloid leukemia in British Columbia. Curr Oncol 2008; 15: 90\u201397.","journal-title":"Curr Oncol"},{"key":"BFleu2017108_CR34","doi-asserted-by":"crossref","unstructured":"Rio DC, Ares M Jr, Hannon GJ, Nilsen TW . Purification of RNA using TRIzol (TRI reagent). Cold Spring Harbor protocols 2010; 2010, pdb prot5439.","DOI":"10.1101\/pdb.prot5439"},{"key":"BFleu2017108_CR35","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1182\/blood-2013-07-516807","volume":"123","author":"K Rothe","year":"2014","unstructured":"Rothe K, Lin H, Lin KB, Leung A, Wang HM, Malekesmaeili M et al. The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem\/progenitor cells. Blood 2014; 123: 3622\u20133634.","journal-title":"Blood"},{"key":"BFleu2017108_CR36","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/nmeth947","volume":"3","author":"O Soderberg","year":"2006","unstructured":"Soderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius KJ, Jarvius J et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 2006; 3: 995\u20131000.","journal-title":"Nat Methods"},{"key":"BFleu2017108_CR37","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3389\/fendo.2013.00126","volume":"4","author":"AM Gonzalez-Jamett","year":"2013","unstructured":"Gonzalez-Jamett AM, Momboisse F, Haro-Acuna V, Bevilacqua JA, Caviedes P, Cardenas AM . Dynamin-2 function and dysfunction along the secretory pathway. Front Endocrinol 2013; 4: 126.","journal-title":"Front Endocrinol"},{"key":"BFleu2017108_CR38","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1091\/mbc.11.2.481","volume":"11","author":"P Nicoziani","year":"2000","unstructured":"Nicoziani P, Vilhardt F, Llorente A, Hilout L, Courtoy PJ, Sandvig K et al. Role for dynamin in late endosome dynamics and trafficking of the cation-independent mannose 6-phosphate receptor. Mol Biol Cell 2000; 11: 481\u2013495.","journal-title":"Mol Biol Cell"},{"key":"BFleu2017108_CR39","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1083\/jcb.201306140","volume":"203","author":"RJ Schulze","year":"2013","unstructured":"Schulze RJ, Weller SG, Schroeder B, Krueger EW, Chi S, Casey CA et al. Lipid droplet breakdown requires dynamin 2 for vesiculation of autolysosomal tubules in hepatocytes. J Cell Biol 2013; 203: 315\u2013326.","journal-title":"J Cell Biol"},{"key":"BFleu2017108_CR40","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1091\/mbc.01-07-0380","volume":"13","author":"EM van Dam","year":"2002","unstructured":"van Dam EM, Stoorvogel W . Dynamin-dependent transferrin receptor recycling by endosome-derived clathrin-coated vesicles. Mol. Biol Cell 2002; 13: 169\u2013182.","journal-title":"Mol. Biol Cell"},{"key":"BFleu2017108_CR41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1078\/0171-9335-00232","volume":"81","author":"K Dunster","year":"2002","unstructured":"Dunster K, Toh BH, Sentry JW . Early endosomes, late endosomes, and lysosomes display distinct partitioning strategies of inheritance with similarities to Golgi-derived membranes. Eur J Cell Biol 2002; 81: 117\u2013124.","journal-title":"Eur J Cell Biol"},{"key":"BFleu2017108_CR42","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1124\/mol.107.034207","volume":"72","author":"A Quan","year":"2007","unstructured":"Quan A, McGeachie AB, Keating DJ, van Dam EM, Rusak J, Chau N et al. Myristyl trimethyl ammonium bromide and octadecyl trimethyl ammonium bromide are surface-active small molecule dynamin inhibitors that block endocytosis mediated by dynamin I or dynamin II. Mol Pharmacol 2007; 72: 1425\u20131439.","journal-title":"Mol Pharmacol"},{"key":"BFleu2017108_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O'Hare","year":"2009","unstructured":"O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16: 401\u2013412.","journal-title":"Cancer Cell"},{"key":"BFleu2017108_CR44","doi-asserted-by":"crossref","unstructured":"Wylie A, Schoepfer J, Berellini G, Cai H, Caravatti G, Cotesta S et al. ABL001, a potent allosteric inhibitor of BCR-ABL, prevents emergence of resistant disease when administered in combination with Nilotinib in an in vivo murine model of chronic myeloid leukemia. Blood 2014; 124: 398 (abstract).","DOI":"10.1182\/blood.V124.21.398.398"},{"key":"BFleu2017108_CR45","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/nprot.2010.84","volume":"5","author":"SV Barysch","year":"2010","unstructured":"Barysch SV, Jahn R, Rizzoli SO . A fluorescence-based in vitro assay for investigating early endosome dynamics. Nat Protoc 2010; 5: 1127\u20131137.","journal-title":"Nat Protoc"},{"key":"BFleu2017108_CR46","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1093\/hmg\/ddq413","volume":"19","author":"AC Durieux","year":"2010","unstructured":"Durieux AC, Vignaud A, Prudhon B, Viou MT, Beuvin M, Vassilopoulos S et al. A centronuclear myopathy-dynamin 2 mutation impairs skeletal muscle structure and function in mice. Hum Mol Genet 2010; 19: 4820\u20134836.","journal-title":"Hum Mol Genet"},{"key":"BFleu2017108_CR47","doi-asserted-by":"crossref","first-page":"20855","DOI":"10.18632\/oncotarget.8028","volume":"7","author":"Y Takahashi","year":"2016","unstructured":"Takahashi Y, Tsotakos N, Liu Y, Young MM, Serfass J, Tang Z et al. The Bif-1-Dynamin 2 membrane fission machinery regulates Atg9-containing vesicle generation at the Rab11-positive reservoirs. Oncotarget 2016; 7: 20855\u201320868.","journal-title":"Oncotarget"},{"key":"BFleu2017108_CR48","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3389\/fonc.2012.00171","volume":"2","author":"S Kongara","year":"2012","unstructured":"Kongara S, Karantza V . The interplay between autophagy and ROS in tumorigenesis. Front Oncol 2012; 2: 171.","journal-title":"Front Oncol"},{"key":"BFleu2017108_CR49","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/bies.201200130","volume":"35","author":"CA Lamb","year":"2013","unstructured":"Lamb CA, Dooley HC, Tooze SA . Endocytosis and autophagy: shared machinery for degradation. Bioessays 2013; 35: 34\u201345.","journal-title":"Bioessays"},{"key":"BFleu2017108_CR50","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.redox.2014.12.003","volume":"4","author":"L Poillet-Perez","year":"2015","unstructured":"Poillet-Perez L, Despouy G, Delage-Mourroux R, Boyer-Guittaut M . Interplay between ROS and autophagy in cancer cells, from tumor initiation to cancer therapy. Redox Biol 2015; 4: 184\u2013192.","journal-title":"Redox Biol"},{"key":"BFleu2017108_CR51","doi-asserted-by":"publisher","first-page":"a018358","DOI":"10.1101\/cshperspect.a018358","volume":"6","author":"SA Tooze","year":"2014","unstructured":"Tooze SA, Abada A, Elazar Z . Endocytosis and autophagy: exploitation or cooperation? Cold Spring Harb Perspect Biol 2014; 6: a018358.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"BFleu2017108_CR52","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1091\/mbc.e08-12-1248","volume":"20","author":"N Hosokawa","year":"2009","unstructured":"Hosokawa N, Hara T, Kaizuka T, Kishi C, Takamura A, Miura Y et al. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell 2009; 20: 1981\u20131991.","journal-title":"Mol Biol Cell"},{"key":"BFleu2017108_CR53","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4161\/auto.8.1.16645","volume":"8","author":"E Wirawan","year":"2012","unstructured":"Wirawan E, Lippens S, Vanden Berghe T, Romagnoli A, Fimia GM, Piacentini M et al. Beclin1: a role in membrane dynamics and beyond. Autophagy 2012; 8: 6\u201317.","journal-title":"Autophagy"},{"key":"BFleu2017108_CR54","doi-asserted-by":"publisher","first-page":"5720","DOI":"10.1093\/emboj\/19.21.5720","volume":"19","author":"Y Kabeya","year":"2000","unstructured":"Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000; 19: 5720\u20135728.","journal-title":"EMBO J"},{"key":"BFleu2017108_CR55","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/cr.2013.166","volume":"24","author":"RC Russell","year":"2014","unstructured":"Russell RC, Yuan HX, Guan KL . Autophagy regulation by nutrient signaling. Cell Res 2014; 24: 42\u201357.","journal-title":"Cell Res"},{"key":"BFleu2017108_CR56","doi-asserted-by":"publisher","first-page":"832704","DOI":"10.1155\/2014\/832704","volume":"2014","author":"M Lippai","year":"2014","unstructured":"Lippai M, Low P . The role of the selective adaptor p62 and ubiquitin-like proteins in autophagy. Biomed Res Int 2014; 2014: 832704.","journal-title":"Biomed Res Int"},{"issue":"19 Pt 1","key":"BFleu2017108_CR57","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1158\/1078-0432.CCR-05-0622","volume":"11","author":"T O'Hare","year":"2005","unstructured":"O'Hare T, Walters DK, Stoffregen EP, Sherbenou DW, Heinrich MC, Deininger MW et al. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src\/Abl inhibitors are compatible with imatinib. Clin Cancer Res 2005; 11 (19 Pt 1): 6987\u20136993.","journal-title":"Clin Cancer Res"},{"key":"BFleu2017108_CR58","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/sj.leu.2403416","volume":"18","author":"AJ Tipping","year":"2004","unstructured":"Tipping AJ, Baluch S, Barnes DJ, Veach DR, Clarkson BM, Bornmann WG et al. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. Leukemia 2004; 18: 1352\u20131356.","journal-title":"Leukemia"},{"key":"BFleu2017108_CR59","doi-asserted-by":"publisher","first-page":"7414","DOI":"10.1073\/pnas.0900653106","volume":"106","author":"M Brehme","year":"2009","unstructured":"Brehme M, Hantschel O, Colinge J, Kaupe I, Planyavsky M, Kocher T et al. Charting the molecular network of the drug target Bcr-Abl. Proc Natl Acad Sci USA 2009; 106: 7414\u20137419.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2017108_CR60","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.molonc.2009.06.002","volume":"3","author":"PP Di Fiore","year":"2009","unstructured":"Di Fiore PP . Endocytosis, signaling and cancer, much more than meets the eye. Preface. Mol Oncol 2009; 3: 273\u2013279.","journal-title":"Mol Oncol"},{"key":"BFleu2017108_CR61","doi-asserted-by":"publisher","first-page":"a016949","DOI":"10.1101\/cshperspect.a016949","volume":"5","author":"I Mellman","year":"2013","unstructured":"Mellman I, Yarden Y . Endocytosis and cancer. Cold Spring Harb Perspect Biol 2013; 5: a016949.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"BFleu2017108_CR62","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrc2521","volume":"8","author":"Y Mosesson","year":"2008","unstructured":"Mosesson Y, Mills GB, Yarden Y . Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer 2008; 8: 835\u2013850.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2017108_CR63","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","volume":"108","author":"M Koptyra","year":"2006","unstructured":"Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M et al. BCR\/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006; 108: 319\u2013327.","journal-title":"Blood"},{"key":"BFleu2017108_CR64","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11899-012-0119-0","volume":"7","author":"N Muvarak","year":"2012","unstructured":"Muvarak N, Nagaria P, Rassool FV . Genomic instability in chronic myeloid leukemia: targets for therapy? Curr Hematol Malig Rep 2012; 7: 94\u2013102.","journal-title":"Curr Hematol Malig Rep"},{"key":"BFleu2017108_CR65","doi-asserted-by":"publisher","first-page":"24273","DOI":"10.1074\/jbc.M002094200","volume":"275","author":"M Sattler","year":"2000","unstructured":"Sattler M, Verma S, Shrikhande G, Byrne CH, Pride YB, Winkler T et al. The BCR\/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 2000; 275: 24273\u201324278.","journal-title":"J Biol Chem"},{"key":"BFleu2017108_CR66","doi-asserted-by":"publisher","first-page":"23631","DOI":"10.18632\/oncotarget.4604","volume":"6","author":"ME Irwin","year":"2015","unstructured":"Irwin ME, Johnson BP, Manshouri R, Amin HM, Chandra J . A NOX2\/Egr-1\/Fyn pathway delineates new targets for TKI-resistant malignancies. Oncotarget 2015; 6: 23631\u201323646.","journal-title":"Oncotarget"},{"key":"BFleu2017108_CR67","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/leu.2009.49","volume":"23","author":"R Naughton","year":"2009","unstructured":"Naughton R, Quiney C, Turner SD, Cotter TG . Bcr-Abl-mediated redox regulation of the PI3K\/AKT pathway. Leukemia 2009; 23: 1432\u20131440.","journal-title":"Leukemia"},{"key":"BFleu2017108_CR68","doi-asserted-by":"publisher","first-page":"34964","DOI":"10.1074\/jbc.M109.013771","volume":"284","author":"PA Singleton","year":"2009","unstructured":"Singleton PA, Pendyala S, Gorshkova IA, Mambetsariev N, Moitra J, Garcia JG et al. Dynamin 2 and c-Abl are novel regulators of hyperoxia-mediated NADPH oxidase activation and reactive oxygen species production in caveolin-enriched microdomains of the endothelium. J Biol Chem 2009; 284: 34964\u201334975.","journal-title":"J Biol Chem"},{"key":"BFleu2017108_CR69","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1179\/102453311X12902908412039","volume":"16","author":"G Can","year":"2011","unstructured":"Can G, Ekiz HA, Baran Y . Imatinib induces autophagy through BECLIN-1 and ATG5 genes in chronic myeloid leukemia cells. Hematology 2011; 16: 95\u201399.","journal-title":"Hematology"},{"key":"BFleu2017108_CR70","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/sj.leu.2404606","volume":"21","author":"A Ertmer","year":"2007","unstructured":"Ertmer A, Huber V, Gilch S, Yoshimori T, Erfle V, Duyster J et al. The anticancer drug imatinib induces cellular autophagy. Leukemia 2007; 21: 936\u2013942.","journal-title":"Leukemia"},{"key":"BFleu2017108_CR71","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1038\/onc.2010.561","volume":"30","author":"BJ Altman","year":"2011","unstructured":"Altman BJ, Jacobs SR, Mason EF, Michalek RD, MacIntyre AN, Coloff JL et al. Autophagy is essential to suppress cell stress and to allow BCR-Abl-mediated leukemogenesis. Oncogene 2011; 30: 1855\u20131867.","journal-title":"Oncogene"},{"key":"BFleu2017108_CR72","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1182\/blood-2010-12-322537","volume":"118","author":"Z Sheng","year":"2011","unstructured":"Sheng Z, Ma L, Sun JE, Zhu LJ, Green MR . BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription. Blood 2011; 118: 2840\u20132848.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2017108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017108","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2017.108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/leu2017108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:07:05Z","timestamp":1684433225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2017108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,3]]},"references-count":72,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["BFleu2017108"],"URL":"https:\/\/doi.org\/10.1038\/leu.2017.108","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,3]]},"assertion":[{"value":"16 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}